Nimotuzumab Increases the Recovery Rate of Severe and Critical COVID-19 Patients: Evaluation in the Real-World Scenario

• Main Authors: Henrry Diaz (Author), Jorge Jiménez (Author), Aray Hernández (Author), Leivis Valdés (Author), Ariadna Martínez (Author), Leonor Porto (Author), Raity Hernández (Author), Nadina Travieso (Author), Julio Héctor Jova (Author), Loipa Medel (Author), Mayelin Troche (Author), Annia Gorte (Author), Delmis Batista (Author), Ana Rosa Valls (Author), Leticia Cabrera (Author), Milagros Domeq (Author), Leslie Pérez (Author), Patricia Lorenzo-Luaces (Author), Lizet Sánchez (Author), Danay Saavedra (Author), Mayra Ramos (Author), Tania Crombet (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

EGFR signaling is an important regulator of SARS-CoV induced lung damage, inflammation and fibrosis. Nimotuzumab is a humanized anti-EGFR antibody registered for several cancer indications. An expanded access study was conducted to evaluate the safety and recovery rate of severe and critical patient...